DSCAM and breast carcinoma: By inhibiting miR-204-5p and enhancing RRM2 expression, DSCAM-AS1 promoted proliferation and suppressed apoptosis of breast cancer cells, indicating the therapeutic potential of DSCAM-AS1/miR-204-5p/RRM2 [49].